Development of ligands for in vivo imaging of cerebral nicotinic receptors

Behavioural Brain Research

Volumn 113, Issue 1-2, 2000, Pages 143-157

  Sihver, Wiebke ^a,c   Nordberg, Agneta ^b   Långström, Bengt ^c   Mukhin, Alexey G ^d   Koren, Andrei O ^d   Kimes, Alane S ^d   London, Edythe D ^d  

^a Department of Medical Pharmacology   (Sweden)

^b Department of Clinical Neuroscience   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Brain imaging; Neurodegenerative disorders; Nicotinic receptor ligands; Positron emission tomography; Single photon emission computed tomography

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; A 84543; EPIBATIDINE; ETHER DERIVATIVE; LIGAND; NICOTINE; NICOTINE DERIVATIVE; NICOTINIC AGENT; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BRAIN RADIOGRAPHY; DEGENERATIVE DISEASE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR AFFINITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BRAIN; BRAIN MAPPING; HUMANS; NEURODEGENERATIVE DISEASES; NICOTINE; RECEPTORS, NICOTINIC; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0033837670     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(00)00209-6     Document Type: Article

References (118)

1. 3H]nicotine to rat brain membranes. Neurochem. Res. 10:1985;259-267.
2. 3H-labeled azetidine analogue of nicotine. Biochem. Pharmacol. 36:1987;2337-2341.
3. Abreo M.A., Lin N.H., Garvey D.S., Gunn D.E., Hettinger A.M., Wasicak J.T., Pavlik P.A., Martin Y.C., Donnelly-Roberts D.L., Anderson D.J., Sullivan J.P., Williams M., Arneric S.P., Holladay M.W. Novel 3-pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. J. Med. Chem. 39:1996;817-825.
4. Adler L.E., Hoffer L.J., Griffith J., Waldo M.C., Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol. Psychiatry. 32:1992;607-616.
5. 3H]ABT-418: a novel cholinergic channel ligand. J. Pharmacol. Exp. Ther. 273:1995;1434-1441.
6. Arneric S.P., Sullivan J.P., Briggs C.A., Donnelly-Roberts D., Anderson D.J., Raszkiewicz J.L., Hughes M.L., Cadman E.D., Adams P., Garvey D.S., Wasicak J.T., Williams M. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization. J. Pharmacol. Exp. Ther. 270:1994;310-318.
7. Badio B., Daly J.W. Epibatidine, a potent analgetic and nicotinic agonist. Mol. Pharmacol. 45:1994;563-569.
8. Badio B., Shi D., Garraffo H.M., Daly J.W. Antinociceptive effects of the alkaloid epibatidine: further studies on involvement of nicotinic receptors. Drug Dev. Res. 36:1995;46-59.
9. Barlow R.B., McLeod L.J. Some studies on cytisine and its methylated derivatives. Br. J. Pharmacol. 35:1969;161-174.
10. 3H]nicotine binding sites in human brain. J. Neurochem. 50:1988;1243-1247.
11. Bertrand S., Patt J.T., Spang J.E., Westera G., Schubiger P.A., Bertrand D. Neuronal nAChR stereoselectivity to non-natural epibatidine derivatives. FEBS Lett. 450:1999;273-279.
12. 3H]nicotine binding in human postmortem brain. J. Pharmacol. Exp. Ther. 282:1997;7-13.
13. 3H]l-nicotine in the mouse brain. Life Sci. 44:1989;1123-1132.
14. 18F]F-A-85380: a PET radioligand for α4β2 nicotinic acetylcholine receptors. Neuroreport. 10:1999;2715-2721.
15. 123I]iodo-A-85380 using single photon emission computed tomography. Life Sci. 63:1998;PL355-PL360.
16. Corey E.J., Loh T.P., AchynthaRao S., Daley D.C., Sarshar S. Stereocontrolled total synthesis of (+)- and (-)-epibatidine. J. Org. Chem. 58:1993;5600-5602.
17. Couturier S., Bertrand D., Matter J.M., Hernandez M.C., Bertrand S., Millar N., Valera S., Barkas T., Ballivet M. A neuronal nicotinic acetylcholine receptor subunit (α7) is developmentally regulated and forms a homo-oligomeric channel blocked by α-BTX. Neuron. 5:1990;847-856.
18. 125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors. J. Pharmacol. Exp. Ther. 282:1997;445-451.
19. Ding Y.S., Gatley J., Fowler J.S., Volkow N.D., Aggarwal D., Logan J., Dewey S.L., Liang F., Carroll F.I., Kuhar M. Mapping nicotinic acetylcholine receptors with PET. Synapse. 24:1996;403-407.
20. 18F]N-methyl-NFEP: kinetics, nicotine effect, and toxicity. Nucl. Med. Biol. 26:1999;139-148.
21. Dolci L., Dolle F., Valette H., Vaufrey F., Fuseau C., Bottlaender M., Crouzel C. Synthesis of a fluorine-18 labeled derivative of epibatidine for in vivo nicotinic acetylcholine receptor PET imaging. Bioorg. Med. Chem. 7:1999;467-479.
22. Dollé F., Dolci L., Valette H., Hinnen F., Vaufrey F., Guenther I., Fuseau C., Coulon C., Bottlaender M., Crouzel C. Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors. J. Med. Chem. 42:1999;2251-2299.
23. Dursun S.M., Reveley M.A., Bird R., Stirton F. Longlasting improvement of Tourette's syndrome with transdermal nicotine. Lancet. 344:1994;1577.
24. 3H]cytisine. Life Sci. 54:1999;1883-1890.
25. Flood P., Role L.W. Neuronal nicotinic acetylcholine receptor modulation by general anesthetics. Toxicol. Lett. 100-101:1998;149-153.
26. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., Kellar K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharmacol. 41:1992;31-37.
27. 3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J. Neurochem. 47:1986;1948-1954.
28. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. USA. 94:1997;587-592.
29. Garvey D.S., Wasicak J., Decker M.W., Brioni J.D., Sullivan J.P., Carrera G.M., Holladay M.H., Arneric S.P., Williams M. Novel isoxazoles which interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and anxiolytic activities. J. Med. Chem. 37:1994;1055-1059.
30. 18F]fluoronochloroepibatidine in rodent and human brain. Nucl. Med. Biol. 25:1998;449-454.
31. Gerzanich V., Anand R., Lindstrom J. Homomers of α8 and β7 subunits of nicotinic receptors exhibit similar channel but contrasting binding site properties. Mol. Pharmacol. 45:1994;212-220.
32. Grünwald F., Biersack H.J., Kuschinsky W. Nicotine receptor mapping. Eur. J. Nucl. Med. 23:1996;1012-1014.
33. 3H]epibatidine to rat brain membranes. Neuroreport. 10:1999;1631-1636.
34. 3H]cytisine. Neuroscience. 62:1994;929-944.
35. Hellström-Lindahl E., Gorbounova O., Seiger Å., Mousavi M., Nordberg A. Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. Dev. Brain Res. 108:1998;147-160.
36. Holladay M.W., Bai H., Li Y., Lin N.H., Daanen J.F., Ryther K.B., Wasicak J., Kincaid J.F., He Y., Hettinger A.M., Huang P., Anderson D.J., Bannon A.W., Buckley M., Campbell J.E., Donnelly-Robert D.L., Gunther K.L., Kim D.J., Kuntzweiler T.A., Sullivan J.P., Decker M.W., Arneric S.P. Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice. Bioorg. Med. Chem. Lett. 8:1998;2797-2802.
37. Holladay M.W., Dart M.J., Lynch J.K. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J. Med. Chem. 40:1997;4169-4194.
38. 18F]fluoro-A-85380, a novel radioligand for in vivo imaging of central nicotinic acetylcholine receptors, Life Sci 2000, in press.
39. 123/125I]iodo-3-(2(S)-zetidinylmethoxy)pyridine: a radioligand for nicotinic acetylcholine receptors. Nucl. Med. Biol. 26:1999;175-182.
40. Horti A., Ravert H.T., London E.D., Dannals R.F. Synthesis of a radiotracer for studying nicotinic acetylcholine receptors: (+/-)-exo-2-(2-[18F]fluoro-5-pyridyl)-7-azabicyclo[2.2.1]heptane. J. Label. Compd. Radiopharm. 38:1996;355-365.
41. 11C]methylated analogues of epibatidine as tracers for positron emission tomographic studies of nicotinic acetylcholine receptors. J. Med. Chem. 41:1998;4199-4206.
42. 18F]fluoro-A-85380, an in vivo tracer for the nicotinic acetylcholine receptors. Nucl. Med. Biol. 25:1998;599-603.
43. Horti A.G., Scheffel U., Stathis M., Finley P., Ravert H.T., London E.D., Dannals R.F. Fluorine-18-FPH for PET-imaging of nicotinic acetylcholine receptors. J. Nucl. Med. 38:1997;1260-1265.
44. 3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. Mol. Pharmacol. 48:1995;280-287.
45. 11C]A-84543: an enantioselective ligand for in vivo studies of neuronal nicotinic acetylcholine receptors. Life Sci. 63:1998;PL13-PL18.
46. Kämpfer I., Sorger D., Schliebs R., Kärger W., Günther K., Schulze K., Knapp W.H. Radioiodination of nicotine with specific activity high enough for mapping nicotinic acetylcholine receptors. Eur. J. Nucl. Med. 23:1996;157-162.
47. Khachaturian Z.S., Radebaugh T.S. Synthesis of critical topics in Alzheimer's disease. Khachaturian Z.S., Radebaugh T.S. Alzheimer's Disease. Cause(s), Diagnosis, Treatment and Care. 1996;3 CRC Press, Boca Raton.
48. Koren A.O., Gündisch D., Horti A., Mukhin A.G., London E.D. 6-[18F]-A-85380-a novel PET ligand for the α4β2 subtype of nicotinic acetylcholine receptors: in vitro characterization. Soc. Neurosci. Abstr. 25:1999;978.
49. Koren A.O., Horti A.G., Mukhin A.G., Gündisch D., Kimes A.S., Dannals R.F., London E.D. 2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. J. Med. Chem. 41:1998;3690-3698.
50. Laruelle M., D'Souza C.D., Baldwin R.M, Abi-Dargham A., Kanes S.J., Fingado C.L., Seibyl J.P., Zoghbi S.S., Bowers M.B., Jatlow P., Charney D.S., Innis R.B. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology. 17:1997;162-174.
51. Liang F., Navarro H.A., Abraham P., Kotlan P., Ding Y.S., Fowler J.S., Volkow N., Kuhar M., Carroll F.I. Synthesis and nicotinic acetylcholine receptor binding properties of exo-2-(2′-fluoro-5′-pyridinyl)-7-azabicyclo-[2.2.1]heptane: a new positron emission tomography ligand for nicotinic receptors. J. Med. Chem. 40:1997;2293-2295.
52. Lindstrom J., Anand R., Peng X., Gerzanich V., Wang F., Li Y. Neuronal nicotinic receptor subtypes. Ann. New York Acad. Sci. 757:1995;100-116.
53. 3H]nicotine binding to putative high affinity receptor sites in rat brain. Mol. Pharmacol. 31:1987;392-400.
54. Loc'h C., Bottlaender M., Kassiou M., Musachio J.L., London E.D., Dannals R.F., Maziere B. Evaluation of a Br-76 analog of epibatidine for PET-imaging of nicotinic acetylcholine receptors. Eur. J. Nucl. Med. 24:1997;913.
55. 76Br]-BrPH: a radiobrominated analog of epibatidine for studies of nicotinic acetylcholine receptors using PET. International Symposium on Radiopharmaceutical Chemistry. Uppsala, Sweden, June 15-19, 1997. p. 519-521, abstract.
56. London E.D., Ball M.J., Waller S.B. Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer's dementia. Neurochem. Res. 14:1989;745-750.
57. 3H]epibatidine. Eur. J. Pharmacol. 278:1995;R1-R2.
58. Lukas R.J. Neuronal nicotinic acetylcholine receptors. Barrantes F.J. The Nicotinic Acetylcholine Receptor: Current Views and Future Trends. 1998;Springer, Berlin.
59. 11C]nicotine binding assessed by PET: a dual tracer model evaluated in the Rhesus monkey brain. Alzheimer Dis. Assoc. Disord. 12:1998;238-246.
60. Marks M.J., Grady S.R., Collins A.C. Downregulation of nicotinic receptor function after chronic nicotine infusion. J. Pharmacol. Exp. Ther. 266:1993;1268-1276.
61. Marks M.J., Stitzel J.A., Collins A.C. Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. J. Pharmacol. Exp. Ther. 235:1985;619-628.
62. 3H](-)nicotine label the same recognition site in rat brain. Mol. Pharmacol. 31:1987;169-174.
63. 3H]epibatidine. Brain Res. 801:1998;143-149.
64. 11C]nicotine: historical aspects. Domino E.F. Brain Imaging of Nicotine and Tobacco Smoking. 1995;13-28 NPP Books, Ann Arbor.
65. Molina P.E., Ding Y.S., Carroll F.I., Liang F., Volkow N.D., Pappas N., Kuhar M., Abumrad N., Gatley S.J., Fowler J.S. Fluoro-norchloroepibatidine: preclinical assessment of acute toxicity. Nucl. Med. Biol. 24:1997;743-747.
66. Mukhin AG, Gündisch D, Horti AG, Koren AO, Tamagnan G, Kimes AS, Chambers J, Vaupel DB, King SI, Picciotto MR, Innis RB, London ED. 5-Iodo-A-85380, an α4β2 subtype-selective ligand for nicotinic acetylcholine receptors, Mol Pharmacol 2000;57:642-649.
67. 125/123I]Iodo-3(2(S)-azetidinylmethoxy)pyridine, a radioiodinated analog of A-85380 for in vivo studies of central nicotinic acetylcholine receptors. Life Sci. 62:1998;PL351-PL357.
68. 125/123I]Iodo-3(2(S)-azetidinylmethoxy)pyridine, a radioiodinated analog of A-85380 for in vivo studies of nicotinic acetylcholine receptors. J. Nucl. Med. 39S:1998;48P.
69. 125/123I)IPH: a radioiodonated analog of epibatidine for in vivo studies of nicotinic acetylcholine receptors. Synapse. 26:1997;392-399.
70. Musachio J.L., Villemange V.L., Scheffel U.A., Dannals R.F., Dogan A.S., Yokoi F., Wong D.F. Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon. Nucl. Med. Biol. 26:1999;201-207.
71. Muzic R.F., Berridge M.S., Friedland R.P., Zhu N., Nelson A.D. PET quantification of specific binding of carbon-11-nicotine in human brain. J. Nucl. Med. 39:1998;2048-2054.
72. Nordberg A, Adem A, Nilsson L, Romanelli L, Zhang X. Heterogeneous cholinergic nicotinic receptors in the CNS, NATO ASI Series 1988;25:331-49.
73. Nordberg A., Adem A., Nilsson L., Winblad B. Nicotinic and muscarinic cholinergic receptor heterogeneity in the human brain at normal aging and dementia of Alzheimer type. New Trends Aging Res. 15:1988;27-36.
74. Nordberg A., Amberla K., Shigeta M., Lundqvist H., Viitanen M., Hellström-Lindahl E., Johansson M., Andersson J., Hartvig P., Lilja A., Långström B., Winblad B. Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis. Assoc. Disord. 12:1998;228-237.
75. 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J. Neural Transm. P-D Sect. 2:1990;215-224.
76. 11C-nicotine in the brains of Rhesus monkey - an attempt to study nicotinic receptors in vivo. J. Neural Transm. P-D Sect. 1:1989;195-205.
77. Nordberg A., Lilja A., Lundqvist H., Amberla K., Viitanen M., Warpman U., Johansson M., Hellström-Lindahl E., Bjurling P., Fasth K.J., Långström B., Winblad B. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol. Aging. 13:1992;747-758.
78. Nordberg A., Lundqvist H., Hartvig P., Andersson J., Johansson M., Hellström-Lindahl E., Långström B. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Dement. Geriatr. Cogn. Disord. 8:1997;78-84.
79. 11C]nicotine in normal and Alzheimer brains - in vivo assessment using positron emission tomography. Alzheimer Dis. Assoc. Disord. 9:1995;21-27.
80. 3H]nicotine binding sites in the rats brain. Drug Alcohol Depend. 16:1985;9-17.
81. 3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci. Lett. 72:1986;115-119.
82. Nybäck H., Nordberg A., Långström B., Halldin C., Hartvig P., Åhlin A., Swahn C.G., Sedvall G. Attempts to visualize nicotinic receptors in the brain of monkey and man by positron emission tomography. Prog. Brain Res. 79:1989;313-319.
83. 11C]nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J. Neural. Transm. P-D Sect. 4:1992;79-95.
84. Parker M.J., Beck A., Luetje C.W. Neuronal nicotinic receptor α2 and β4 subunits confer large differences in agonist binding affinity. Mol. Pharmacol. 54:1998;1132-1139.
85. Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain, Prog Neurobiol 2000;61:75-111.
86. Patt J.T., Spang J.E., Westera G., Buck A., Schubiger P.A. Synthesis and in vivo studies of [C-11]N-methylepibatidine: comparison of the stereoisomers. Nucl. Med. Biol. 26:1999;165-173.
87. Peng X., Gerzanich V., Anand R., Whiting P.J., Lindstrom J. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol. Pharmacol. 46:1994;523-530.
88. Perry D.C., Dávila-García M.I., Stockmeier C.A., Kellar K.J. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J. Pharmacol. Exp. Ther. 289:1999;1545-1552.
89. 3H]epibatidine labels nicotinic receptors in rat brain: an autoradiographic study. J. Pharmacol. Exp. Ther. 275:1995;1030-1034.
90. Perry E.K., Court J.A., Lloyd S., Johnson M., Griffiths M.H., Spurden D., Piggott M.A., Turner J., Perry R.H. Amyloidosis in normal aging and transmitter signaling in human temporal lobe. Ann. New York Acad. Sci. 777:1996;388-392.
91. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G., Irving D., Brown A., Perry R.H. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience. 64:1995;385-395.
92. Prince R.J., Sine S.M. Epibatidine binds with unique site and state selectivity to muscle nicotinic acetylcholine receptors. J. Biol. Chem. 263:1998;7843-7849.
93. 3H]nicotine to rat brain membranes and its inhibition by analogues of nicotine. Neuropharmacology. 27:1988;235-241.
94. Saji H., Watanabe A., Magata Y., Ohmomo Y., Kiyono Y., Yamada Y., Iida Y., Yonekura Y., Konishi J., Yokoyama A. Synthesis and characterization of radioiodinated (S)-5-iodonicotine: a new ligand for potential imaging of brain nicotinic cholinergic receptors by single photon emission computed tomography. Chem. Pharm. Bull. 45:1997;284-290.
95. Sanberg P.R., Silver A.A., Shytle R.D., Philipp M.K., Cahill D.W., Fogelson H.M., McConville B.J. Nicotine for the treatment of Tourette's syndrome. Pharmacol. Ther. 74:1997;21-25.
96. 125I]dexetimide and a simple probe. Eur. J. Pharmacol. 358:1998;207-211.
97. 18F]Fluro-A-85380: an in vivo tracer for the nicotinic acetylcholine receptor. Nucl. Med. Biol. 27:2000;51-56.
98. Scheffel U., Taylor G.F., Kepler J.A., Carroll G.I., Kuhar M.J. In vivo labeling of neuronal nicotinic acetylcholine receptors with radiolabeled isomers of norchloroepibatidine. Neuroreport. 6:1995;2483-2488.
99. Schwartz R.D., Kellar K.J. Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science. 220:1983;214-216.
100. Seeman J.I., Secor H.V., Forrest G. J. Label. Compd. Radiopharm. 16:1979;387.
101. 76Br]bromo-3-[[2(S)-azetidinyl]methoxy]pyridine, a novel nicotinic acetylcholine receptor ligand, in rat brain. J. Neurochem. 73:1999;1264-1272.
102. 11C-labeled (S)(-)nicotine, (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole, and (R,S)-1-methyl-2-(3-pyridyl)azetidine as nicotinic receptor ligands for positron emission tomography studies. J. Neurochem. 71:1998;1750-1760.
103. 11C]nicotine in Rhesus monkeys. Nucl. Med. Biol. 26:1999;633-640.
104. 3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease. Neuroscience. 94:1999;685-696.
105. Steinlein O.K., Mulley J.C., Propping P., Wallace R.H., Phillips H.A., Sutherland G.R., Scheffer I.E., Berkovic S.F. A missense mutation in the neuronal nicotinic acetylcholine receptor α4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat. Genet. 11:1995;201-203.
106. Sullivan J.P., Donnelly-Robert D.L., Briggs C.A., Anderson D.J., Gopalakrishnan M., Piattoni-Kaplan M., Campbell J.E., McKenna D.G., Molinari E., Hettinger A.M., Garvey D.S., Wasicak J.T., Holladay M.W., Williams M., Arneric S.P. A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand. Neuropharmacology. 35:1996;725-734.
107. 18F]fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine in vivo. Life Sci. 64:1999;PL93-PL97.
108. 18F]fluoro-A-85380. J. Nucl. Med. 40:1999;1374-1380.
109. 11C]-methylcytisine. Nucl. Med. Commun. 18:1997;164-168.
110. 125I]5-I-A-85380, a nicotinic acetylcholine receptor radioligand. Neuroreport. 9:1998;2311-2317.
111. Villemagne V.L., Horti A.G., Scheffel U., Ravert H.T., Finley P., Clough D.J., London E.D., Wagner H.N. Jr, Dannals R.F. Imaging nicotinic acetylcholine receptors with fluorine-18-FPH, an epibatidine analog. J. Nucl. Med. 38:1997;1737-1741.
112. Violet J.M., Downie D.L., Nakisa R.C., Lieb W.R., Franks N.P. Differential sensitivities of mammalian neuronal and muscle nicotinic acetylcholine receptors to general anesthetics. Anesthesiology. 86:1997;866-874.
113. 11C]raclopride in the human brain. Synapse. 16:1994;255-262.
114. Whiteaker P., Sharples C.G., Wonnacott S. Agonist-induced up-regulation of α4β2 nicotinic acetylcholine receptors in M10 cells: pharmacological and spatial definition. Mol. Pharmacol. 53:1998;950-962.
115. 3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiography study. Neurology. 38:1988;720-723.
116. Xiao Y., Meyer E.L., Thompson J.M., Surin A., Wroblewski J., Kellar K.J. Rat α3/β4 subtype of neuronal nicotinic acetylcholine receptor stably expressed in a transfected cell line: pharmacology of ligand binding and function. Mol. Pharmacol. 54:1998;322-333.
117. Zhang X., Gong Z.H., Fasth K.J., Långström B., Nordberg A. Interaction of the nicotinic agonist (R,S)-3-pyridyl-1-methyl-2-(3-pyridyl)-azetidine (MPA) with nicotinic acetylcholine receptor subtypes expressed in cell lines and rat cortex. Neurochem. Int. 32:1998;435-441.
118. Zhang X., Gong Z.H., Hellström-Lindahl E., Nordberg A. Regulation of α4β2 nicotinic acetylcholine receptors in M10 cells following treatment with nicotinic agents. Neuroreport. 6:1995;313-317.